Premium
Inconsistent immunohistochemical expression of lymphatic and blood endothelial cell markers in cutaneous lymphangiomas
Author(s) -
Bhawan Jag,
Silva Claudine,
Taungjaruwinai Wirach Matt
Publication year - 2013
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12184
Subject(s) - cd31 , lymphangioma , immunohistochemistry , medicine , pathology , hemangioma , lymphatic system , confidence interval
Purpose We sought to describe expression of the immunohistochemical markers, CD31 , D2 ‐40 and LYVE ‐1 (lymphatic vessel hyaluronan receptor‐1), that may assist in differentiating cutaneous lymphangioma and cutaneous hemangioma. Methods Immunohistochemical staining of lymphangioma and hemangioma specimens was completed with CD31 , D2 ‐40 and LYVE ‐1 antibodies. Results Thirty‐three examples of lymphangioma and 13 examples of hemangioma were evaluated. CD31 was positive in 91% of lymphangioma and 100% of hemangioma (sensitivity 0.91, 95% confidence interval 0.75‐0.98; specificity 0, 95% confidence interval 0‐0.28). D2 ‐40 was positive in 54% of lymphangioma and 23% in hemangioma (sensitivity 0.50 95% confidence interval 0.32‐0.68; specificity 0.50 95% confidence interval 0.28‐0.72). LYVE ‐1 was positive in 6% in lymphangioma and 15% hemangioma (sensitivity 0.06 95% confidence interval 0.01‐0.22, specificity 0.85 95% confidence interval 0.54‐0.97). Conclusions Due to the similar embryonic origins, it is unlikely that a single marker may accurately differentiate the lymphangioma from hemangioma. A combination of immunohistochemical stains such CD31 , D2 ‐40 and LYVE ‐1 testing may potentially increase the diagnostic accuracy in differentiating lymphangioma from hemangioma. However, our findings suggest that there is no advantage in performing immunohistochemical staining to differentiate lymphangioma from hemangioma.